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R-banded karyotype showing the paracentric inversion of chromosome 16 and double trisomies 9 and 22. diagnosis, as the bone marrow is not involved. 3, 4 Our patient had a diagnosis of lymphoma before recognizing that it was a GS.
Cytogenetic analysis of AML patients with chloroma have rarely been reported in the literature. However, it appears that patients with t(8;21)-associated AML type 2 are more prone than others to develop GS. Indeed, 4.5 to 38% of patients with t(8;21)(q22;q22) developed GS. 1, 5 Several patients with AML type 4 in conjunction with GS and abnormalities of chromosome 16, mainly inv(16)(p13;q22) have also been reported. 3, [6] [7] [8] However, isolated granulocytic sarcoma of the small intestine preceding AML is rare; only two patients had a cytogenetic analysis using banding techniques. Le Beau et al 8 Etiology of acute myeloid leukemia following intensive therapy for AML -relapse, secondary disease or bad luck? Leukemia (2002) Our patient has several features in common with the latter case (inv(16) and double trisomies 9 and 22), but for the absence of eosinophilia and the type of AML which is definitely of the FAB type 2; however, the blasts composing the granulocytic sarcoma had some monocytic characteristics which were not found in the marrow at the diagnosis of the AML. Therefore, to the best of our knowledge, this is the first report of a case of GS preceding AML type 2 with inv(16). Leukemia (FISH) were negative. A relapse in November 1998 was associated with reappearance of the original clone with trisomy 13 (no further chromosomal aberrations) which remained refractory to reinduction treatment. Following conditioning therapy (total body irradiation (2 Gy), anti-thymocyte globuline, cyclophosphamide) and peripheral blood stem cell transplantation from a female HLA-identical unrelated donor a complete remission was achieved. Analyses of short-tandem repeats (STRs) as highly specific individual genetic markers demonstrated the presence of hematopoiesis of donor origin. Moreover, FISH analysis for trisomy 13 was equally negative for 4 months confirming the absence of trisomy 13 containing blasts. In October 1998 -ie 5 months after BMT and 1. years after the initial diagnosis -myeloid blasts were again detected. However, this time cytogenetic analyses demonstrated complete absence of the initially observed trisomy 13, instead a translocation (1;5) and a monosomy 7 were observed in the AML blasts. STR analysis proved the recipient origin of the AML blasts. Cytoreductive therapy was initiated to facilitate planned adoptive immunotherapy as the sole remaining therapeutic option. The patient was transplanted with peripheral blood stem cells from the original donor with no further conditioning therapy. Granulocyte-macrophage colony-stimulating factor (GM-CSF) was applied to induce the formation of antigen-presenting cells (APCs) followed by transplantation of donor T cells and stimulation by interleukin 2. Severe acute graftversus-host disease of the skin occurred but the leukemia was only insufficiently controlled. Three months later the diseased progressed and with no further treatment available the patient died 26 months after the initial diagnosis.
F Morel
The tragic clinical course of this patient with AML is -in our opinion -very instructive for two reasons: (1) The crescendo of treatment imposed on this patient is a paradigm of current intensive multimodal antileukemic chemo-and immunotherapy featuring its potential and its shortcomings. (2) It illustrates that -when AML follows AML -the underlying pathogenesis might be considerably more complex than 'classical relapse', requiring appropriate diagnostic and therapeutic consequences. These two aspects will be further discussed.
Concerning (1): Therapy in this patient comprised intensive chemotherapy 1 including an autologous PBSCT during first line treatment followed by -in the course of relapsed disease -myeloablative conditioning by radiochemotherapy preceding allogeneic BMT. Immunotherapy consisted of the graft-versus-leukemia effect of the 'conventional' allo-BMT and the allo-PBSCT (without prior conditioning). However, in face of diminishing chimerism during the second reappearance of AML the latter was primarily intended to allow for adoptive immunotherapy by donor lymphocyte infusions (DLI) followed by interleukin 2-induced T cell stimulation. 2 This approach was complemented by efforts to induce maturation of AML blasts for increased immune recognition by GM-CSF (granulocyte-macrophage colony-stimulating factor) and of primitive hematopoietic progenitor cells of donor origin to mature into dendritic cells for increased crosspresentation of leukemic antigens. 3 Concerning (2): The clinical course of this patient was remarkable in so far that an AML featuring a trisomy 13 became clinically manifest twice and was then followed by a treatment-refractory AML with monosomy 7 that ultimately resulted in the death of the patient. Whereas the detection of the trisomy 13 clearly indicated that the first reappearance of AML constituted a 'classical' relapse the origin of the second AML reappearance (by definition not necessarily 'relapse') is more complex. The situation when AML follows AML can be summarized schematically as depicted in Figure 1 . In the present case with no trisomy 13 detectable at second reappearance (thereby already excluding options A, B, D) the very rare and unusual possibility of a donor leukemia (option F), ie an AML derived from donor hematopoiesis following allogeneic HSCT, could be ruled out by detection of STDs (short tandem repeats) of recipient origin in the AML blasts. This finding indicated that this disease was derived from the patient's own hematopoiesis despite having achieved 'complete' chimerism shortly after her allogeneic BMT. However, the question remained whether this disease was 'new' or just the old AML 'in disguise'. In fact, it was not possible to completely rule out option C from our schema which describes the reappearance of a so far undetected subclone of the original leukemia which might potentially display substantial differences in detectable cytogenetic aberrations as compared to the so far dominating clone but is, nevertheless, derived from a common leukemic ancestor cell. 4 However, there are several lines of evidence that clearly support the view that the '−7 AML' was in fact a secondary (and thereby by definition a new and 'biologically' unrelated) AML which was most likely induced by the intensive cytotoxic treatment for her initial '+13 AML'.
(1) Assuming the '+13 AML' and the '−7 AML' to be offspring of a common leukemic ancestor would imply that this original clone had no cytogenetic aberration and that secondary clones developed the two differing karyotypes; or that in addition to that they simultaneously lost cytogenetic aberrations if the original clone had had any -a very unlikely constellation. (2) The monosomy 7 seen in the second reappearance of AML is a typical aberration seen in treatment-related AML or myelodysplasia (t-AML, t-MDS) , 5 typically following treatment with ionising radiation or alkylating agents. AraC. Topo II inhibitors are especially well known inducers of secondary leukemias, however they are typically, although not exclusively, associated with 11q23 aberrations, 6 which was not the case in this patient. (4) The time-frame of the '−7 AML' becoming clinically manifest 18 months after the initial diagnosis of the '+13 AML' is compatible with the development of a secondary AML induced by intensive genotoxic therapy in the months following the initial diagnosis. 7 Although it may be argued that later genotoxic insults such as the unsuccesful reinduction or the conditioning regimen might be responsible for leukemogenesis, the short time period between these insults and the clinical manifestation of a t-AML (especially in the case of the allogeneic BMT, which preceded the '−7 AML' by only 4 months) makes these latter events less likely to be the primary inducers of that AML -potential induction of secondary alterations in already transformed leukemic population notwithstanding.
These lines of evidence indicate that the '−7 AML' in this patient was in fact a secondary leukemia and therefore a separate entity, 7 most likely induced by the antileukemic treatment for the initial '+13 AML'. Assuming this interpretation to be correct the following interesting conclusions about the two leukemias can be drawn: Even though the '+13 AML' could be cytoreduced by intensive chemotherapy the early relapse (8 months after the initial diagnosis, 2 months after completion of the autologous PBSCT) indicates the still insufficient intensity of this treatment for this particular AML. However, in contrast to the S-HAI cycle preceding the autologous PBSCT, which is only intensely myelosuppressive but not myeloablative (in fact S-HAI is commonly used as reinduction chemotherapy in relapsed AML with no stem cell support resulting in prolonged periods of neutropenia of about 40 days), the myeloablative conditioning therapy preceding the allogeneic BMT (and the subsequent graft-versus-leukemia effects?) were apparently able to better control or even to eradicate that particular AML. Over a period of observation of 12 months from the time of her allogeneic BMT until death from the '−7 AML' no sign of the prior '+13 AML' could be detected, which was already a substantially longer '+13 leukemia-free period' at a later (and thereby prognostically even more unfavorable) disease stage than following her initial treatment.
This sequence was in contrast to the behavior of the '−7 AML': No monosomy 7 or t(1;5) was detectable following induction chemotherapy or at relapse of the '+13 AML'. Assuming that the leukemogenic hits responsible for the '−7 AML' in fact occurred during firstline treatment this implies that potentially already during autologous PBSCT but quite certainly during conditioning and allogeneic BMT the −7 clone was present at a low and with conventional methods undetectable tumor burden, ie at minimal residual disease (MRD) status. Therefore coexistence of two unrelated acute myleloid leukemias over a significant period of time must be postulated. In how far the substantial fluctuations in '+13 AML' tumor load per se (remissionrelapse-remission) had any quantitative impact on '−7 AML' growth kinetics during its undetected MRD phase evidently cannot be ascertained but at least was qualitatively compatible with viable coexistence. During the time of coexistence the growth kinetics of the '−7 AML' were apparently inferior to those of the '+13 AML' with the '+13 AML' but no '−7 AML' reappearing at first relapse -in fact studies on the proliferative activity of the '−7 AML' were perfomed ex vivo, which gave a very low result for leukemic bulk proliferation (0.04
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Schema of potential relationships between AML diagnosis following a prior AML. H-thymidine incorporation). These results are compatible with prior studies by our group that have shown that a low proliferative activity is associated with prognostically unfavorable karyotypes such as monosomy 7 and constitutes one mechanism for a decreased sensitivity towards AraC-induced cytotoxicity and worse treatment response. 8 No data were available for the '+13 AML'. The documented, unfavorable, responses of the '−7 AML' to treatment are restricted to the effects of the second allogeneic HSCT, the cytoreductive treatment with idarubicin and mitoxantrone preceding it and the subsequent adoptive immunotherapy with donor lymphocytes and GM-CSF/IL2. However, the treatment refractory nature of Leukemia this disease becomes even more obvious when one considers that, even though unwittingly at the time, the '−7 AML' had undergone myeloablative conditioning and an allogeneic BMT at a very low tumour burden/MRD status, ie in an ideal setting, but proved not to be eradicated by this intensive procedure.
In conclusion, the clinical course of this patient stresses four items: (1) Current intensified antileukemic treatment comprising intensive chemotherapy, myeloablation and immunotherapy is able to cytoreduce and eradicate some types of AML; (2) its intensity restricts its use to a subgroup of patients with adaequate performance status; (3) the antileukemic treatment itself may be the reason for secondary neo-plasms especially treatment-related acute myeloid leukemias; (4) the substantial subgroup of AML with unfavorable cytogenetics often remains ultimately resistant not only to intensive chemotherapy but also to current immunotherapeutic approaches, and urgently requires new and more effective modalities of treatment.
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